We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

44 hedge funds and large institutions have $27.2M invested in Aevi Genomic Medicine Inc in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more capital invested

Capital invested by funds: $14.6M → $27.2M (+$12.7M)

2% less funds holding

Funds holding: 45 → 44 (-1)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

Holders
44
Holders Change
-1
Holders Change %
-2.22%
% of All Funds
1.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
5
Reduced
14
Closed
7
Calls
$27K
Puts
–
Net Calls
+$27K
Net Calls Change
+$15K

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$2.15M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$344K
3
JP Morgan Chase
JP Morgan Chase
New York
+$186K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$164K
5
TD Asset Management
TD Asset Management
Ontario, Canada
+$94.6K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$74.9K
2
ARTA
A.R.T. Advisors
New York
-$50K
3
Millennium Management
Millennium Management
New York
-$34.7K
4
Citadel Advisors
Citadel Advisors
Florida
-$30.2K
5
Wells Fargo
Wells Fargo
California
-$25.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
MWP
26
MYCIO Wealth Partners
Pennsylvania
$20K +$18.8K +10,000 New
WAP
27
Wealthcare Advisory Partners
Pennsylvania
$10K – – –
Morgan Stanley
28
Morgan Stanley
New York
$7K -$9.77K -5,202 -60%
MAM
29
Meeder Asset Management
Ohio
$5K -$1.6K -853 -25%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$4K -$47 -25 -1%
LA
31
Legacy Advisors
Pennsylvania
$4K – – –
KCPG
32
Kavar Capital Partners Group
Kansas
$3K +$2.82K +1,500 New
UBS Group
33
UBS Group
Switzerland
$2K -$12.2K -6,503 -87%
Bank of America
34
Bank of America
North Carolina
$2K – – –
IWM
35
IHT Wealth Management
Illinois
$2K – – –
LTFS
36
Ladenburg Thalmann Financial Services
Florida
$2K – – –
TWA
37
TCI Wealth Advisors
Arizona
$2K – – –
AG
38
Advisor Group
Arizona
$1K – – –
IA
39
IFP Advisors
Florida
$1K – – –
KTC
40
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$4 – – –
ARTA
42
A.R.T. Advisors
New York
– -$50K -41,879 Closed
Macquarie Group
43
Macquarie Group
Australia
– -$8K -7,058 Closed
CHP
44
Cable Hill Partners
Oregon
– -$5K -4,000 Closed
CA
45
Calton & Associates
Florida
– -$2K -1,225 Closed
Barclays
46
Barclays
United Kingdom
– -$186 -99 -59%
Simplex Trading
47
Simplex Trading
Illinois
– -$54 -29 Closed
Group One Trading
48
Group One Trading
Illinois
– +$188 +100 New
1
2

GNMX Hedge Fund Activity: Q1 2018 in Review

44 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q1 2018, worth a combined $27.2M — up 87% from $14.6M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of GNMX and 6 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 5 added.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $2.15M. The largest seller was Renaissance Technologies, cutting an estimated $74.9K.

  • 44 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q1 2018, down from 45 in Q4 2017.
  • Funds reported $27.2M of Aevi Genomic Medicine Inc stock for Q1 2018, up 87% quarter-over-quarter.
  • 6 funds opened new Aevi Genomic Medicine Inc positions in Q1 2018 and 7 closed out, a net change of -1 holder.
  • The largest Aevi Genomic Medicine Inc buyer in Q1 2018 was T. Rowe Price Associates, an estimated $2.15M added.
  • The largest Aevi Genomic Medicine Inc seller in Q1 2018 was Renaissance Technologies, an estimated $74.9K sold.

Based on aggregated 13F filings for Q1 2018.